The Europe API Intermediate Market would witness market growth of 6.7% CAGR during the forecast period (2023-2030).
The prevalence of chronic diseases like cardiac, orthopedic, gastrointestinal, and other conditions is predicted to rise as the senior population grows. As a result, this aspect is anticipated to support the market. Due to several variables, including inactivity, fragility, obesity, and other illnesses, including diabetes and arteriosclerosis, the senior population is particularly vulnerable to cardiac diseases.
Additionally, the alarming rise in comorbid conditions, including diabetes, high cholesterol, and blood pressure, can raise their chance of acquiring heart illnesses. Therefore, the risk of getting cardiac diseases rises as the population ages, leading to a sedentary lifestyle. The demand for cardiovascular medications and the API intermediates used in their formulation is thus expected to rise as the number of older populations suffering from heart disease grows. This reason, therefore, fuels the market's expansion.
As per the UK governments report named “Future of an ageing population”, by 2040, in UK, nearly one in seven people is projected to be aged over 75. By 2037, there are projected to be 1.42 million more households headed by someone aged 85 or over an increase of 161% over 25 years. According to report on the French ageing policy, published by UN; as in other European countries, France faces a continuous and significant increase in the number of elderly people: in 2012, there were 15 million of people aged more than 60 years old in France. This number will reach 24 million in 2060. Considering this rising aging population, the market is anticipated to grow in the region as the aged people are more at a risk of encountering numerous chronic diseases.
The Germany market dominated the Europe API Intermediate Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $14.8 billion by 2030. The UK market is estimated to witness a CAGR of 5.8% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 7.5% during (2023 - 2030).
Based on Type, the market is segmented into Bulk Drug Intermediates, and Chemical Intermediates. Based on End User, the market is segmented into Biotech & Pharmaceutical Companies, CMO, and Others. Based on Application, the market is segmented into Analgesics, Antidiabetic Drugs, Anti-Infective Drugs, Cardiovascular Drugs, Anticancer Drugs, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide API Intermediate Market is Projected to reach USD 237.7 Billion by 2030, at a CAGR of 7.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cation Pharma, Espee Group, Sandoo Pharmaceuticals and Chemicals Co., Ltd., Cipla Limited, Cambrex Corporation, Vertellus, Dr. Reddy’s Laboratories Ltd., Evonik Industries AG (RAG-Stiftung), Pfizer, Inc., Shree Ganesh Remedies Limited.
By Type
By End User
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
